December 18, 2009

ODAC votes against erlotinib as maintenance therapy for advanced NSCLC

By Kelley Luckstein

Yesterday, the FDA Oncologic Drugs Advisory Committee voted 12-1 against recommending the use of erlotinib as first-line maintenance monotherapy for patients with advanced non-small cell lung cancer…


The most common adverse events with erlotinib were rash and diarrhea, according to data presented. Ronald Richardson, MD, of the division of medical oncology at the Mayo Clinic in Rochester, Minn., was one of the panelists who voted against the therapy. “We were presented with a single study that has some design flaws showing so


HemOnc Today, 12/17/09

Tags: Cancer, erlotinib, Lung Cancer

Please sign in or register to post a reply.
Contact Us · Privacy Policy